Custom-Made vaccine takes on ovarian cancer

NCT ID NCT03839524

Completed Disease control Sponsor: Transgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations and given as injections to help the immune system recognize and attack any remaining cancer cells. The main goal was to check safety and tolerability, with some early looks at whether it might help prevent recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TG4050 (a personalized cancer vaccine made from the patient's own tumor mutations)
What this could lead to: If successful, this could point toward a new way to keep ovarian cancer from coming back after standard treatment.
What could go wrong: This is an early Phase 1 trial with only 64 participants, so it is mainly checking safety, not yet proven to work. The treatment is personalized and complex, which may limit how widely it can be used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma peritoneal carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CARCINOMA PERITONEAL CARCINOMA

Contacts and locations

Locations

Hôpital Pitié-Salpêtrière

Paris, 75013, France
IUCT Toulouse

Toulouse, 31100, France
Institut Curie

Paris, 75005, France
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic Phoenix

Phoenix, Arizona, 85259, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.